Recent Updates
Recently added Catalysts
SHPH Negative Sentiment

Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter

Friday, August 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Shuttle Pharmaceuticals Holdings, Inc. has announced that it is not in compliance with NASDAQ's periodic filing requirements due to its failure to submit its Quarterly Report. This noncompliance is based on the Nasdaq Listing Rule 5250(c)(1). The situation poses a risk to the company's continued listing on the exchange.

Market Sentiment Analysis

CONCERNS & RISKS

  • Shuttle Pharmaceuticals failed to file its Quarterly Report.
  • The company received a noncompliance letter from NASDAQ.
  • This noncompliance could impact its continued listing on NASDAQ.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
10.2%
average across 2 past catalysts
Cash runway
~0 mo
High dilution risk

Full Press Release Details

Gaithersburg, Maryland–(Newsfile Corp. – August 28, 2026) – Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (the “Company” or “Shuttle”), today announced that the Company is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form […]

Frequently Asked Questions

What did Shuttle Pharmaceuticals announce?

Shuttle Pharmaceuticals announced it is not in compliance with NASDAQ's filing requirements.

What caused the noncompliance issue?

The issue arose from the company's failure to file its Quarterly Report.

What rule did Shuttle violate?

Shuttle violated Nasdaq Listing Rule 5250(c)(1).

What is the impact of this noncompliance?

This noncompliance could affect Shuttle's continued listing on NASDAQ.

ShareAdd on Google
Tags: SHPH Viatris Investor Conferences Healthcare Shuttle Pharmaceuticals NASDAQ noncompliance Quarterly Report
Last updated: Aug 28, 2026

Biotech snapshot

Cash runway
$1M liquidity · $1M/mo burn
~0 mo
High dilution risk

Catalyst track record

+24%
best trade around SHPH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SHPH.

See every catalyst's timing & PoA →